Immunotherapy’s Wild Ride: From neglect to stardom to pariah — and now maybe phoenix Recap

After a decade of highs and hard lessons, immunotherapy is entering a new phase—less about hype, more about engineering. Panelists called for smarter platforms, better trial design, and therapies built with patients in mind. Cell therapy isn’t being discarded; it’s being redesigned for durability, access, and scale. This isn’t retreat—it’s reset. The future of IO lies in understanding what works, why it works, and how to make it work for more people.

Framing the immunotherapy reset

The immuno-oncology field didn’t just grow—it boomed. From 2011 to 2017, PD-1 and PD-L1 inhibitors ushered in a wave of approvals and investment that made checkpoint therapy the new backbone of cancer care. But as the decade wore on, the landscape grew crowded, combinations piled up, and enthusiasm began to outpace understanding.

Panelists described this arc in blunt terms. The field rose from neglect to stardom—and then, in many ways, to overhype and disappointment. “Checkpoint, checkpoint, checkpoint… that space just hasn’t held up,” Jeff Bockman, PhD, Executive Vice President of Oncology at Lumanity . “We’re seeing too many redundancies, not enough distinction.”